First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Three private biotechs enter clinical trials, one targeting KRAS.
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.
Prexasertib data worsen again, and biomarkers are up in the air.
Readout of the Pivot-006 trial is brought forward by nearly a year.
The company secures funding to push its lead candidate towards US approval.
